Private label desloratadine coming
This article was originally published in The Tan Sheet
Executive Summary
Perrigo may launch a desloratadine anti-allergy product in July 2012 or sooner under circumstances outlined in a recent Hatch-Waxman litigation settlement, the Allegan, Mich.-based private labeler announced Dec. 4. The allergy product is equivalent to Schering-Plough's Clarinex 5 mg tablets, which Wolters Kluwer estimates sold $300 million in the 12 months ending October 2008, Perrigo says. The firm says it may launch the product as a prescription or OTC product depending on its status at the time of the launch
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.